Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial

David Cella, Bernard Escudier, Nizar M. Tannir, Thomas Powles, Frede Donskov, Katriina Peltola, Manuela Schmidinger, Daniel Y. C. Heng, Paul N. Mainwaring, Hans J. Hammers, Jae Lyun Lee, Bruce J. Roth, Florence Marteau, Paul Williams, John Baer, Milan Mangeshkar, Christian Scheffold, Thomas E. Hutson, Sumanta Pal, Robert J. MotzerToni K. Choueiri

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

Alkuperäiskielienglanti
LehtiJournal of Clinical Oncology
Vuosikerta36
Numero8
Sivut757-+
Sivumäärä11
ISSN0732-183X
DOI - pysyväislinkit
TilaJulkaistu - 10 maaliskuuta 2018
OKM-julkaisutyyppiA1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

  • 3122 Syöpätaudit

Lainaa tätä

Cella, David ; Escudier, Bernard ; Tannir, Nizar M. ; Powles, Thomas ; Donskov, Frede ; Peltola, Katriina ; Schmidinger, Manuela ; Heng, Daniel Y. C. ; Mainwaring, Paul N. ; Hammers, Hans J. ; Lee, Jae Lyun ; Roth, Bruce J. ; Marteau, Florence ; Williams, Paul ; Baer, John ; Mangeshkar, Milan ; Scheffold, Christian ; Hutson, Thomas E. ; Pal, Sumanta ; Motzer, Robert J. ; Choueiri, Toni K. / Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma : METEOR Phase III Randomized Trial. Julkaisussa: Journal of Clinical Oncology. 2018 ; Vuosikerta 36, Nro 8. Sivut 757-+.
@article{7004e08797db44a0930bdae2598d041b,
title = "Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial",
keywords = "SYMPTOM INDEX FKSI, FUNCTIONAL ASSESSMENT, OPEN-LABEL, THERAPY, KIDNEY, SURVIVAL, PLACEBO, GROWTH, CANCER, INHIBITOR, 3122 Cancers",
author = "David Cella and Bernard Escudier and Tannir, {Nizar M.} and Thomas Powles and Frede Donskov and Katriina Peltola and Manuela Schmidinger and Heng, {Daniel Y. C.} and Mainwaring, {Paul N.} and Hammers, {Hans J.} and Lee, {Jae Lyun} and Roth, {Bruce J.} and Florence Marteau and Paul Williams and John Baer and Milan Mangeshkar and Christian Scheffold and Hutson, {Thomas E.} and Sumanta Pal and Motzer, {Robert J.} and Choueiri, {Toni K.}",
year = "2018",
month = "3",
day = "10",
doi = "10.1200/JCO.2017.75.2170",
language = "English",
volume = "36",
pages = "757--+",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

Cella, D, Escudier, B, Tannir, NM, Powles, T, Donskov, F, Peltola, K, Schmidinger, M, Heng, DYC, Mainwaring, PN, Hammers, HJ, Lee, JL, Roth, BJ, Marteau, F, Williams, P, Baer, J, Mangeshkar, M, Scheffold, C, Hutson, TE, Pal, S, Motzer, RJ & Choueiri, TK 2018, 'Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial', Journal of Clinical Oncology, Vuosikerta 36, Nro 8, Sivut 757-+. https://doi.org/10.1200/JCO.2017.75.2170

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma : METEOR Phase III Randomized Trial. / Cella, David; Escudier, Bernard; Tannir, Nizar M.; Powles, Thomas; Donskov, Frede; Peltola, Katriina; Schmidinger, Manuela; Heng, Daniel Y. C.; Mainwaring, Paul N.; Hammers, Hans J.; Lee, Jae Lyun; Roth, Bruce J.; Marteau, Florence; Williams, Paul; Baer, John; Mangeshkar, Milan; Scheffold, Christian; Hutson, Thomas E.; Pal, Sumanta; Motzer, Robert J.; Choueiri, Toni K.

julkaisussa: Journal of Clinical Oncology, Vuosikerta 36, Nro 8, 10.03.2018, s. 757-+.

Tutkimustuotos: ArtikkelijulkaisuArtikkeliTieteellinenvertaisarvioitu

TY - JOUR

T1 - Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

T2 - METEOR Phase III Randomized Trial

AU - Cella, David

AU - Escudier, Bernard

AU - Tannir, Nizar M.

AU - Powles, Thomas

AU - Donskov, Frede

AU - Peltola, Katriina

AU - Schmidinger, Manuela

AU - Heng, Daniel Y. C.

AU - Mainwaring, Paul N.

AU - Hammers, Hans J.

AU - Lee, Jae Lyun

AU - Roth, Bruce J.

AU - Marteau, Florence

AU - Williams, Paul

AU - Baer, John

AU - Mangeshkar, Milan

AU - Scheffold, Christian

AU - Hutson, Thomas E.

AU - Pal, Sumanta

AU - Motzer, Robert J.

AU - Choueiri, Toni K.

PY - 2018/3/10

Y1 - 2018/3/10

KW - SYMPTOM INDEX FKSI

KW - FUNCTIONAL ASSESSMENT

KW - OPEN-LABEL

KW - THERAPY

KW - KIDNEY

KW - SURVIVAL

KW - PLACEBO

KW - GROWTH

KW - CANCER

KW - INHIBITOR

KW - 3122 Cancers

U2 - 10.1200/JCO.2017.75.2170

DO - 10.1200/JCO.2017.75.2170

M3 - Article

VL - 36

SP - 757-+

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -